Sernova (XTER:PSH) Debt-to-Equity

: 0.17 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

Sernova's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.09 Mil. Sernova's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.55 Mil. Sernova's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$3.83 Mil. Sernova's debt to equity for the quarter that ended in Jan. 2024 was 0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sernova's Debt-to-Equity or its related term are showing as below:

XTER:PSH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.17
Current: 0.17

During the past 13 years, the highest Debt-to-Equity Ratio of Sernova was 0.17. The lowest was 0.01. And the median was 0.01.

XTER:PSH's Debt-to-Equity is ranked worse than
52.15% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs XTER:PSH: 0.17

Sernova Debt-to-Equity Historical Data

The historical data trend for Sernova's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.01

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.17

Competitive Comparison

For the Biotechnology subindustry, Sernova's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Sernova's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sernova's Debt-to-Equity falls into.

Sernova Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sernova's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.136	+	0)	/	12.515
	=	0.01

Sernova's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.088	+	0.546)	/	3.834
	=	0.17

Sernova (XTER:PSH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sernova Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sernova's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (XTER:PSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (XTER:PSH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.

Sernova (XTER:PSH) Debt-to-Equity

Sernova Debt-to-Equity Historical Data

Sernova Debt-to-Equity Calculation

Sernova Debt-to-Equity Related Terms

Sernova (XTER:PSH) Business Description

Sernova (XTER:PSH) Headlines